Senti Biosciences, Inc. (SNTI)

NASDAQ: SNTI · IEX Real-Time Price · USD
2.07
-0.12 (-5.48%)
At close: Jun 28, 2022 4:00 PM
2.09
+0.02 (0.97%)
After-hours: Jun 28, 2022 7:59 PM EDT
-5.48%
Market Cap 90.37M
Revenue (ttm) 2.76M
Net Income (ttm) -55.32M
Shares Out 43.66M
EPS (ttm) -3.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 472,031
Open 2.21
Previous Close 2.19
Day's Range 2.02 - 2.24
52-Week Range 1.91 - 10.54
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About SNTI

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf... [Read more...]

Industry Biotechnology
Founded 2016
Employees 89
Stock Exchange NASDAQ
Ticker Symbol SNTI
Full Company Profile

Financial Performance

In 2021, SNTI's revenue was $2.76 million, an increase of 387.81% compared to the previous year's $566,000. Losses were -$55.32 million, 178.5% more than in 2020.

Financial Statements

News

Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with ...

- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combinatio...

Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-...

Synthetic Biology Platform Senti Bio Rides On Omid Farokhzad's SPAC For NASDAQ Debut

Senti Biosciences Inc, the synthetic biology play helmed by MIT whiz Tim Lu, will be merging with Farokhzad's Dynamics Special Purpose Corp (NASDAQ: DYNS) in a deal set to deliver $296 million in gross ...

Other symbols: AMGN

Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Compan...

- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock...

Cathie Wood Makes Adjustments to Portfolio in August

Catherine Wood (Trades, Portfolio) disclosed last week her firm, ARK Investment Management, made a number of changes to its portfolio in August.

Other symbols: FATEMASSQSIVUZI

Dynamics Special Purpose Corp. Announces Pricing of $200 Million Initial Public Offering

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dynamics Special Purpose Corp. Announces Pricing of $200 Million Initial Public Offering